These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease. Cassidy MR; Roberts JS; Bird TD; Steinbart EJ; Cupples LA; Chen CA; Linnenbringer E; Green RC Alzheimers Dement; 2008 Nov; 4(6):406-13. PubMed ID: 19012865 [TBL] [Abstract][Full Text] [Related]
3. [Attitudes towards predictive genetic testing for Alzheimer's disease]. Illes F; Bernhardt T; Prell K; Rietz C; Rudinger G; Frölich L; Maier W; Rietschel M Z Gerontol Geriatr; 2006 Jun; 39(3):233-9. PubMed ID: 16794889 [TBL] [Abstract][Full Text] [Related]
4. Support for a tax increase to provide unrestricted access to an Alzheimer's disease medication: a survey of the general public in Canada. Oremus M; Tarride JE; Clayton N; Raina P BMC Health Serv Res; 2009 Dec; 9():246. PubMed ID: 20040110 [TBL] [Abstract][Full Text] [Related]
5. Genetic screening for Alzheimer's disease: what factors predict intentions to take a test? Frost S; Myers LB; Newman SP Behav Med; 2001; 27(3):101-9. PubMed ID: 11985183 [TBL] [Abstract][Full Text] [Related]
6. The role of test accuracy in predicting acceptance of genetic susceptibility testing for Alzheimer's disease. Bassett SS; Havstad SL; Chase GA Genet Test; 2004; 8(2):120-6. PubMed ID: 15345108 [TBL] [Abstract][Full Text] [Related]
7. Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Roberts JS; LaRusse SA; Katzen H; Whitehouse PJ; Barber M; Post SG; Relkin N; Quaid K; Pietrzak RH; Cupples LA; Farrer LA; Brown T; Green RC Alzheimer Dis Assoc Disord; 2003; 17(2):86-93. PubMed ID: 12794385 [TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
9. The general public's willingness to pay for tax increases to support unrestricted access to an Alzheimer's disease medication. Oremus M; Tarride JE; Raina P; Thabane L; Foster G; Goldsmith CH; Clayton N Pharmacoeconomics; 2012 Nov; 30(11):1085-95. PubMed ID: 22938161 [TBL] [Abstract][Full Text] [Related]
10. Patients' willingness-to-pay for an Alzheimer's disease medication in Canada. Oremus M; Tarride JE; Pullenayegum E; Clayton N; ; Raina P Patient; 2013; 6(3):161-8. PubMed ID: 23716166 [TBL] [Abstract][Full Text] [Related]
11. Evolving attitudes to Alzheimer's disease among the general public and caregivers in Europe: findings from the IMPACT survey. Wortmann M; Andrieu S; Mackell J; Knox S J Nutr Health Aging; 2010 Aug; 14(7):531-6. PubMed ID: 20818467 [TBL] [Abstract][Full Text] [Related]
12. Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. Roberts JS Gerontologist; 2000 Feb; 40(1):43-52. PubMed ID: 10750312 [TBL] [Abstract][Full Text] [Related]
13. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial. Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843 [TBL] [Abstract][Full Text] [Related]
14. Medication for Alzheimer's disease and associated fall hazard: a retrospective cohort study from the Alzheimer's Disease Neuroimaging Initiative. Epstein NU; Guo R; Farlow MR; Singh JP; Fisher M Drugs Aging; 2014 Feb; 31(2):125-9. PubMed ID: 24357133 [TBL] [Abstract][Full Text] [Related]
15. Attitudes and knowledge about presymptomatic genetic testing among individuals at high risk for familial, early-onset Alzheimer's disease. Marcheco B; Bertoli AM; Rojas I; Heredero L Genet Test; 2003; 7(1):45-7. PubMed ID: 12820702 [TBL] [Abstract][Full Text] [Related]
16. A new scale measuring psychologic impact of genetic susceptibility testing for Alzheimer disease. Chung WW; Chen CA; Cupples LA; Roberts JS; Hiraki SC; Nair AK; Green RC; Stern RA Alzheimer Dis Assoc Disord; 2009; 23(1):50-6. PubMed ID: 19266699 [TBL] [Abstract][Full Text] [Related]
17. Genetic testing and Alzheimer's disease: implications for psychiatric-mental health nursing. Schutte DL J Psychosoc Nurs Ment Health Serv; 2013 Nov; 51(11):14-8. PubMed ID: 24124693 [TBL] [Abstract][Full Text] [Related]
18. Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. Kopits IM; Chen C; Roberts JS; Uhlmann W; Green RC Genet Test Mol Biomarkers; 2011 Dec; 15(12):871-5. PubMed ID: 21749214 [TBL] [Abstract][Full Text] [Related]
19. Genetic susceptibility for Alzheimer's disease: why did adult offspring seek testing? Hurley AC; Harvey FR; Roberts JS; Wilson-Chase C; Lloyd S; Prest J; Lock M; Horvath KJ; Green RC Am J Alzheimers Dis Other Demen; 2005; 20(6):374-81. PubMed ID: 16396443 [TBL] [Abstract][Full Text] [Related]
20. To know or not to know: an update of the literature on the psychological and behavioral impact of genetic testing for Alzheimer disease risk. Rahman B; Meiser B; Sachdev P; Barlow-Stewart K; Otlowski M; Zilliacus E; Schofield P Genet Test Mol Biomarkers; 2012 Aug; 16(8):935-42. PubMed ID: 22731638 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]